Iterum Therapeutics PLC
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Iterum Therapeutics' stock with a target price of $6.50, indicating significant growth potential.
Financial Health
Iterum Therapeutics is generating moderate cash flow per share, indicating steady financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ITRM
Targeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Trial readouts and regulatory decisions can move value materially, though outcomes are binary and may cause sharp share‑price swings.
Antibiotic development focus
Works on anti‑infective treatments addressing resistant bacteria — an area with medical need but known regulatory and commercial hurdles.
Capital and liquidity
Micro‑cap status means thin trading and potential funding needs; watch cash runway and any planned capital raises.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
